Mineralys Therapeutics (MLYS) Stock Forecast: StockMap's 2-Week Call

MLYS stock forecast: StockMap's model makes no two-week call on Mineralys Therapeutics after the Nov 19 close: its evidence is split, 5 reasons for and 10 against. Right in 4 of 4 two-week windows on MLYS since Sep 15; by chance, a call on the same dates was right 56% of the time.

Mineralys Therapeutics last closed at $14.16, +2.76% on the session.

Against the IVW growth benchmark the position is +5.09% over the forecast window.

Mineralys Therapeutics' market cap is $1.25B as of November 19, 2026.

No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -15 (too close to call).

Where MLYS sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

16 daily calls for MLYS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Mineralys Therapeutics in the 15th percentile on return on equity, where 100 is best.

Mineralys Therapeutics is classified under Health Care / Biotechnology.

StockMap tracks Mineralys Therapeutics as the 118th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.

On that composite Mineralys Therapeutics ranks 134th of 394 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Mineralys Therapeutics (MLYS) — StockMap 2-week forecast & tracked accuracy